SenesTech Inc (NASDAQ:SNES) saw a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 3,005,577 shares, an increase of 1,088.9% from the May 15th total of 252,800 shares. Approximately 22.2% of the company’s stock are sold short. Based on an average daily volume of 10,015,816 shares, the short-interest ratio is currently 0.3 days.
SNES has been the subject of several analyst reports. Zacks Investment Research upgraded shares of SenesTech from a “sell” rating to a “hold” rating in a report on Thursday, February 22nd. Roth Capital reiterated a “buy” rating on shares of SenesTech in a report on Wednesday, April 4th. Finally, ValuEngine upgraded shares of SenesTech from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.
Shares of SNES stock opened at $1.63 on Friday. The stock has a market capitalization of $29.11 million, a PE ratio of -1.45 and a beta of 3.78. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.65 and a quick ratio of 4.89. SenesTech has a one year low of $0.30 and a one year high of $6.40.
A hedge fund recently bought a new stake in SenesTech stock. Sabby Management LLC bought a new stake in SenesTech Inc (NASDAQ:SNES) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 436,863 shares of the company’s stock, valued at approximately $315,000. Sabby Management LLC owned about 2.77% of SenesTech at the end of the most recent reporting period. Institutional investors own 22.09% of the company’s stock.
SenesTech Company Profile
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including plant-based fertility control, feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.